UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000050023
Receipt number R000056989
Scientific Title Evaluation of D-aspartic acid, Zinc and Co-enzyme Q 10 supplementation on different semen parameters in idiopathic male infertility: a randomized double blind placebo controlled study
Date of disclosure of the study information 2023/02/14
Last modified on 2024/03/13 08:20:48

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of D-aspartic acid, Zinc and Co-enzyme Q 10 supplementation on different semen parameters in idiopathic male infertility: a randomized double blind placebo controlled study

Acronym

Evaluation of D-aspartic acid, Zinc and Co-enzyme Q 10 supplementation on different semen parameters in idiopathic male infertility: a randomized double blind placebo controlled study

Scientific Title

Evaluation of D-aspartic acid, Zinc and Co-enzyme Q 10 supplementation on different semen parameters in idiopathic male infertility: a randomized double blind placebo controlled study

Scientific Title:Acronym

Evaluation of D-aspartic acid, Zinc and Co-enzyme Q 10 supplementation on different semen parameters in idiopathic male infertility: a randomized double blind placebo controlled study

Region

Africa


Condition

Condition

male infertility

Classification by specialty

Urology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Evaluation of D-aspartic acid, Zinc and Co-enzyme Q 10 supplementation on different semen parameters in idiopathic male infertility

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

improvement of different semen parameters

Key secondary outcomes

change in free testosterone level


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation

YES

Institution consideration

Institution is considered as adjustment factor in dynamic allocation.

Blocking

YES

Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Group A will d-aspartic acid daily for 3 months

Interventions/Control_2

Group B will receive placebo daily for 3 months

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

25 years-old <=

Age-upper limit

40 years-old >=

Gender

Male

Key inclusion criteria

Any infertile male aged 25 to 40 years old suffering from idiopathic infertility will be included

Key exclusion criteria

Any idiopathic infertile male suffering from varicocele or leukocytospermia or immunological infertility will be excluded. Finally, any infertile patient with small testicular volume < 8 ml will be also excluded

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Sameh
Middle name Fayek
Last name GamalEl Din

Organization

Cairo university

Division name

Andrology

Zip code

002

Address

New Cairo

TEL

01227109309

Email

samehfayek@hotmail.com


Public contact

Name of contact person

1st name Sameh
Middle name Fayek
Last name GamalEl Din

Organization

Cairo university

Division name

Andrology

Zip code

002

Address

New cairo

TEL

01227109309

Homepage URL

https://medicine.cu.edu.eg/.../124-kasralainy-school-of-medicine

Email

samehfayek@kasralainy.edu.eg


Sponsor or person

Institute

Cairo university

Institute

Department

Personal name

sameh fayek gamalel din


Funding Source

Organization

parkville pharmaceutical company

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Egyptian


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kasr Alainy faculty of medicine

Address

New Cairo

Tel

01227109309

Email

samehfayek@kasralainy.edu.eg


Secondary IDs

Secondary IDs

YES

Study ID_1

Sameh fayek gamalel din

Org. issuing International ID_1

Cairo university

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 02 Month 14 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

100

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2023 Year 02 Month 08 Day

Date of IRB

2023 Year 02 Month 14 Day

Anticipated trial start date

2023 Year 03 Month 14 Day

Last follow-up date

2023 Year 04 Month 19 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 01 Month 12 Day

Last modified on

2024 Year 03 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056989


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name